Supplier News: Cambrex, Kindeva, Alcami, Catalent & More
The latest from CDMOs, CMOs, and suppliers featuring Cambrex, Aptar Pharma, Kindeva, Alcami, Catalent, DFE Pharma, and Codis.
Chemicals/Chemical API Manufacturing
* Cambrex Breaks Ground on $120-M Small-Molecule, Peptide Expansion
Formulation Development/Drug Product Manufacturing
* Codis Provides Update on Spray-Drying Expansion
Packaging
* Aptar Acquires Pulmotree for Non-Propellant Liquid Inhaler Platform
Appointments
* Alcami Names VP of Laboratory Services
* Catalent Names Group President, Pharma & Consumer Health
* DFE Pharma Names New COO
* Kindeva Names EVP of Inhalation & Specialty Drug Delivery
Chemicals/Chemical API Manufacturing
Cambrex Breaks Ground on $120-M Small-Molecule, Peptide Expansion
Cambrex has broken ground on a $120-million expansion at its Charles City, Iowa, facility, which will add 160,000 liters of manufacturing capacity to increase the site’s total capacity by approximately 25% to nearly one million liters to support the development and commercial manufacturing of small-molecule active pharmaceutical ingredients (APIs) and synthetic peptides. The project is anticipated to be completed in the fourth quarter of 2028.
The Charles City facility provides development and manufacturing services for small-molecule APIs, synthetic peptides, and pharmaceutical intermediates from clinical development through commercial-scale production.
Source: Cambrex
Formulation Development/Drug Product Manufacturing
Codis Provides Update on Spray-Drying Expansion
Codis, a CDMO specializing in spray drying, amorphous solid dispersions (ASDs), and particle engineering, has provided an update on its ongoing PSD-4 expansion at the company’s site in Haverhill, UK.
The demolition of existing redundant facilities is now complete, which makes space for the construction of a new building and the next stage of Codis’ investment in a GEA Pharma-SD type PSD-4 solvent-capable spray dryer. Following installation and validation, the PSD-4 spray dryer will expand Codis’ commercial-scale solvent-based spray-drying capacity for ASDs. The PSD-4 expansion remains on schedule, with the next key milestone, the Dryer Factory Acceptance Test, due to take place in November. The new spray-dying capacity is expected to become available in the last quarter of 2027.
Source: Codis
Packaging
Aptar Acquires Pulmotree for Non-Propellant Liquid Inhaler Platform
Aptar Pharma, a provider of services and products used in drug delivery, dosing, and protection technologies, has acquired Pulmotree, a Munich, Germany-based life-sciences company specializing in pulmonary drug-delivery systems for targeted delivery to the lungs. The acquisition is expected to accelerate the development, industrialization, and commercialization of Pilmotree’s proprietary Kolibri non-propellant liquid inhaler platform capable of supporting the delivery of complex molecules, including biologics. Non-propellant liquid inhalers encompass nebulizers and soft-mist inhalers and are being developed as an alternative to propellant-based systems.
Source: Aptar Pharma
Appointments
Alcami Names VP of Laboratory Services
Alcami, a CDMO of drugs products and provider of contract analytical testing services, has promoted Robert Tragas to Vice President, Laboratory Services. In his expanded role, he will lead laboratory operations across Alcami’s Research Triangle Park, North Carolina, campus, overseeing analytical, biologics, microbiology, and environmental monitoring functions. He joined Alcami more than 26 years ago and has held positions of increasing responsibility throughout the company.
Source: Alcami
Catalent Names Group President, Pharma & Consumer Health
Catalent named Wetteny Joseph, formerly Executive Vice President and Chief Financial Officer of the animal-health company, Zoetis, as Group President, Pharma and Consumer Health (PCH), effective November 2, 2026.
In this role, he will lead Catalent’s PCH segment focusing on oral delivery technologies and manufacturing for small and macro molecules and advanced delivery of self-care products. He joined Catalent’s Group Executive Committee and is reporting directly to Alessandro Maselli, the company’s President and Chief Executive Officer. He succeeds Aris Gennadios, PhD, who is leaving to pursue outside opportunities after a long-tenured career at Catalent that began in 2002.
Prior to his role at Zoetis, Joseph held other senior leadership roles at Catalent, including Senior Vice President and Chief Financial Officer and President of Clinical Supply Services.
Source: Catalent
DFE Pharma Names New COO
DFE Pharma, a manufacturer of pharmaceutical excipients, appointed Peter Rose, formerly Vice President and Managing Director at LGC, as Chief Operating Officer (COO), effective September 1, 2026. He succeeds Teun Heijnen, who had served as COO and who will retire at the end of 2026.
Source: DFE Pharma
Kindeva Names EVP of Inhalation & Specialty Drug Delivery
Kindeva, a CDMO specializing in complex drug and combination product delivery, has appointed Daniel Couto, formerly Chief Operating Officer of Vedanta Biosciences, a bio/pharmaceutical company specializing in live biotherapeutic products to treat gastrointestinal diseases, as Executive Vice President, Inhalation & Specialty Drug Delivery. He will have executive responsibility for the strategy, growth, and performance of Kindeva’s global Inhalation & Specialty Drug Delivery business, which encompasses capabilities across inhalation, nasal, dermal, and transdermal drug delivery.
Overall, Couto has more than 30 years of biopharmaceutical experience spanning drug development, GMP manufacturing, operations, and organizational leadership. Prior to his role at Vedanta Biosciences, he held senior positions at ContraFect, Merck Sharp & Dohme, and Avecia Biologics.
Source: Kindeva
